The technology, protected by four international Patent Applications, has been proved at a lab and pilot scale, and now is being scaled-up for commercial and industrial purposes.

At its latter level, the technology comprises simple, reproducible and inexpensive procedures.

The size of nanopcapsules has been carefully adjusted in order to avoid the nanomaterial label as defined by the Recommendation of the European Commission on the definition of nanomaterial as published on 18 October 2011. Moreover, full toxicological studies (acute and sub-chronic) and biodistribution assays using radioisotopes (125I and 67Ga) has assessed safety of the developed nanocapsules.